中国生物科技服务(08037.HK)拟540万美元出售164万股Broncus优先股以专注核心业务
格隆汇8月30日丨中国生物科技服务(08037.HK)宣布,于2019年8月30日,本公司拟向中国新证财经资讯有限公司出售目标公司增利控股有限公司全部已发行股本及股东贷款,有关代价为540万美元。
目标公司主要业务为投资控股。目标公司持有164万股Broncus的B系列优先股,相当于Broncus的已发行股本总额约2.05%。Broncus及其附属公司主要从事研发及制造治疗肺病病人所采用的导向、诊断及治疗技术。
本集团认为,出售事项将为本公司提供机会,可将其于Broncus的投资变现,并将让本集团可专注于其核心业务。于出售事项完成后,本公司将不再持有目标公司及Broncus的任何权益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.